GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.

GlaxoSmithKline is discussing with FDA whether Paxil data indicating an increased risk of "emotional lability" in pediatric patients on paroxetine should be communicated to physicians